Journal article
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Abstract
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.
METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching …
Authors
Green JB; Bethel MA; Armstrong PW; Buse JB; Engel SS; Garg J; Josse R; Kaufman KD; Koglin J; Korn S
Journal
New England Journal of Medicine, Vol. 373, No. 3, pp. 232–242
Publisher
Massachusetts Medical Society
Publication Date
July 16, 2015
DOI
10.1056/nejmoa1501352
ISSN
0028-4793